• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of thoraxThoraxInstructions for authorsInstructions for authors
Thorax. Apr 2004; 59(4): 334–336.
PMCID: PMC1763796

Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients

Abstract

Background: Chronic pulmonary infection with transmissible Pseudomonas aeruginosa strains in individuals with cystic fibrosis (CF) has been reported, raising issues of cross infection and patient segregation. The first such strain to be described (the Liverpool epidemic strain, LES) is now widespread in many UK CF centres. However, whether such infection carries a worse prognosis is unknown. To address this, the clinical course of a group of CF patients chronically infected by LES was compared with that in patients harbouring unique strains.

Methods: Using P aeruginosa strain genotyping, two cohorts of CF patients attending the Liverpool CF service were identified who were LES positive or negative in 1998 and remained so until 2002. From these, two groups of 12 patients were matched in 1998 for age, spirometric parameters, and nutritional state and their clinical course was followed for 5 years. Patients chronically infected with Burkholderia cepacia were excluded.

Results: Patients chronically infected with LES had a greater annual loss of lung function than those not chronically infected by LES (mean difference between groups -4.4% (95% CI -8.1 to -0.9; p<0.02)), and by 2002 their percentage predicted forced expiratory volume in 1 second (FEV1) was worse (mean 65.0% v 82.6%, p<0.03). Their nutritional state also deteriorated over the study period (mean difference between groups in body mass index -0.7 (95% CI -1.2 to -0.2; p<0.01)), such that by 2002 they were malnourished compared with LES negative patients (mean BMI 19.4 v 22.7, p<0.02).

Conclusions: Chronic infection with the Liverpool epidemic P aeruginosa strain in CF patients confers a worse prognosis than infection with unique strains alone, confirming the need for patient segregation. Since this strain is common in many CF units, strain identification in all CF centres is essential. This can only be carried out using genomic typing methods.

Full Text

The Full Text of this article is available as a PDF (180K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, Heaf DP, van Saene H, Hart CA. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996 Sep 7;348(9028):639–642. [PubMed]
  • Jones AM, Govan JR, Doherty CJ, Dodd ME, Isalska BJ, Stanbridge TN, Webb AK. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet. 2001 Aug 18;358(9281):557–558. [PubMed]
  • Pitt TL. Cross infection of cystic fibrosis patients with Pseudomonas aeruginosa. Thorax. 2002 Nov;57(11):921–921. [PMC free article] [PubMed]
  • Geddes DM. Of isolates and isolation: Pseudomonas aeruginosa in adults with cystic fibrosis. Lancet. 2001 Aug 18;358(9281):522–523. [PubMed]
  • Jones AM, Dodd ME, Doherty CJ, Govan JRW, Webb AK. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax. 2002 Nov;57(11):924–925. [PMC free article] [PubMed]
  • McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet. 2001 Aug 18;358(9281):558–560. [PubMed]
  • Ojeniyi B, Petersen US, Høiby N. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS. 1993 Feb;101(2):168–175. [PubMed]
  • Williams T. Evaluation of antimicrobial sensitivity patterns as markers of Pseudomonas aeruginosa cross-infection at a cystic fibrosis clinic. Br J Biomed Sci. 1997 Sep;54(3):181–185. [PubMed]
  • Grundmann H, Schneider C, Hartung D, Daschner FD, Pitt TL. Discriminatory power of three DNA-based typing techniques for Pseudomonas aeruginosa. J Clin Microbiol. 1995 Mar;33(3):528–534. [PMC free article] [PubMed]
  • Parsons Yasmin N, Panagea Stavroula, Smart Catherine H M, Walshaw Martin J, Hart C Anthony, Winstanley Craig. Use of subtractive hybridization to identify a diagnostic probe for a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. J Clin Microbiol. 2002 Dec;40(12):4607–4611. [PMC free article] [PubMed]
  • Malerba Mario, Ponticiello Antonio, Radaeli Alessandro, Bensi Giuliano, Grassi Vittorio. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther. 2004;17(1):27–34. [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...